The US FDA has posted details, including company and FDA Briefing Materials, for the Wednesday, July 13, 2016, Arthritis Advisory Committee (AAC) meeting about biologics license application (BLA) 761042, for GP2015 (or GP 2015), a proposed biosimilar to Amgen Inc.’s Enbrel (etanercept) submitted by Sandoz, Inc. (Sandoz), a unit of Novartis AG.
See the SAC Tracker report